INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
Abbott Reports First-Quarter Results
Our key products helped deliver impressive growth, exceeding expectations and jump-starting another strong year.
We just closed the books on the first quarter of 2019 and our key products are helping to deliver another strong start for Abbott.
For the quarter, we delivered sales growth of more than 7% (on an organic basis) and exceeded our previous ongoing earnings-per-share guidance thanks to key products such as FreeStyle Libre, Alinity and MitraClip. We are also seeing several other bright spots throughout our portfolio in our medical devices, nutrition and established pharma businesses.
And, our innovative pipeline and focused execution is continuing to pay off. We saw more than 10 significant product approvals and developments in the first quarter alone.
Some of the highlights include:
For full financials, you can read our press release, or take a look at some additional materials below:
Abbott's Chairman and CEO Miles D. White shared his views on first-quarter performance:
Learn more about Abbott's first-quarter 2019 results:
Download a summary of Abbott's earnings highlights here.
For more information on Abbott's earnings results, see the news release.
*Alinity m is in development and not commercially available in the United States for diagnostic use.